Synaffix’s glycan-based antibody–drug conjugate technology is experiencing ... programs based on the Synaffix platform. The business model of Synaffix is based on technology out-licensing ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting ... by GlobeNewswire. The model used to summarize ...
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona ...
Synaffix, a rapidly growing Dutch biotechnology company, offers a clinical-stage antibody–drug conjugate (ADC ... The business model of Synaffix is based on technology out-licensing, which ...
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback